The optimal treatment for patients with stage I non-small cell lung cancer: Minimally invasive lobectomy versus stereotactic ablative radiotherapy – A nationwide cohort study

Over the past decades, the optimal treatment for stage I non-small cell lung cancer (NSCLC) has been subject of debate. For operable patients, a lobectomy with systematic lymph node dissection, preferably minimally invasive by video-assisted thoracoscopic surgery (VATS), is recommended by (inter)national guidelines [1 –3]. However, since encouraging results have been obtained with stereotactic ablative radiotherapy (SABR) in inoperable patients, SABR is increasingly being used in operable patients as well [4,5], despite minimal evidence of equipoise between the two treatment modalities.

Source: Lung Cancer - April 11, 2024 Category: Cancer & Oncology Authors: Julianne Cynthia de Ruiter, Vincent van der Noort, Judi Nani Annet van Diessen, Egbert Frederik Smit, Ronald Alphons Maria Damhuis, Koen Johan Hartemink, on behalf of the ESLUNG group Source Type: research